We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+19.02%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$2.7B
AUM Growth
-$133M
Cap. Flow
-$358M
Cap. Flow %
-13.27%
Top 10 Hldgs %
54.24%
Holding
107
New
20
Increased
12
Reduced
35
Closed
22

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$157M
2
OMDA
Omada Health Inc
OMDA
+$42M
3
ROIV icon
Roivant Sciences
ROIV
+$36.1M
4
CAI
Caris Life Sciences
CAI
+$29.6M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$17.8M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$104M
2
FOLD
Amicus Therapeutics
FOLD
+$90.7M
3
SLNO
Soleno Therapeutics
SLNO
+$80.5M
4
VRNA
Verona Pharma
VRNA
+$78.2M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$42.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAI
26
Caris Life Sciences
CAI
$4.66B
$29.3M 1.09%
+1,098,163
New +$29.6M
XBI icon
27
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$24.9M 0.92%
+300,000
New +$23.9M
ISRG icon
28
Intuitive Surgical
ISRG
$122B
$24.5M 0.91%
45,119
+4,500
+11% +$2.35M
ADMA icon
29
ADMA Biologics
ADMA
$2.02B
$23.7M 0.88%
1,303,468
-69,765
-5% -$1.42M
BBNX
30
Beta Bionics
BBNX
$770M
$23.2M 0.86%
1,593,608
– –
SYRE icon
31
Spyre Therapeutics
SYRE
$8.7B
$22.9M 0.85%
1,529,445
-783,827
-34% -$11.6M
EOLS icon
32
Evolus
EOLS
$377M
$22.8M 0.85%
2,474,843
-1,654,299
-40% -$16.9M
CELC icon
33
Celcuity
CELC
$4.31B
$21.8M 0.81%
1,633,208
-729,071
-31% -$7.94M
DYN icon
34
Dyne Therapeutics
DYN
$3.92B
$21.4M 0.79%
2,247,390
-66,013
-3% -$727K
SION
35
Sionna Therapeutics
SION
$2.23B
$21.1M 0.78%
1,216,045
-35,056
-3% -$459K
AXSM icon
36
Axsome Therapeutics
AXSM
$11.8B
$20.7M 0.77%
198,534
-156,573
-44% -$16.6M
RGEN icon
37
Repligen
RGEN
$8.31B
$20.6M 0.77%
166,000
+36,199
+28% +$4.61M
PODD icon
38
Insulet
PODD
$11.4B
$19M 0.7%
60,387
-11,210
-16% -$3.24M
OM icon
39
Outset Medical
OM
$77.9M
$16M 0.59%
833,333
– –
ZYME icon
40
Zymeworks
ZYME
$1.78B
$16M 0.59%
1,275,274
-589,398
-32% -$7.02M
CTMX icon
41
CytomX Therapeutics
CTMX
$788M
$15.9M 0.59%
+6,993,646
New +$11.3M
ALDX icon
42
Aldeyra Therapeutics
ALDX
$102M
$15.5M 0.58%
4,051,631
-5,224,220
-56% -$13.5M
CRL icon
43
Charles River Laboratories
CRL
$10.8B
$15.2M 0.56%
+100,000
New +$13.3M
CNTA
44
DELISTED
Centessa Pharmaceuticals
CNTA
$15.1M 0.56%
1,146,935
-1,893,460
-62% -$24M
INBX icon
45
Inhibrx
INBX
$1.28B
$14M 0.52%
977,892
-86,134
-8% -$1.11M
ADGM
46
Adagio Medical Holdings
ADGM
$11.8M
$12.8M 0.48%
9,876,576
+64,157
+0.7% +$73.1K
NRIX icon
47
Nurix Therapeutics
NRIX
$2.4B
$12.5M 0.46%
1,096,985
+799,432
+269% +$8.64M
TVTX icon
48
Travere Therapeutics
TVTX
$5.27B
$12.3M 0.46%
+834,252
New +$13.8M
OBIO icon
49
Orchestra BioMed
OBIO
$220M
$12.3M 0.46%
4,592,556
– –
DRUG
50
Bright Minds Biosciences
DRUG
$747M
$11M 0.41%
420,690
-23,959
-5% -$718K
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Perceptive Advisors held 107 positions worth $2.7B, down 4.7% from $2.83B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Perceptive Advisors withdrew a net $358M in Q2 2025, closing 22 positions and reducing 35 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $104M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Ascendis Pharma A/S worth $166M.

  • Perceptive Advisors's largest Q2 2025 buy was Ascendis Pharma A/S: 963,886 shares worth $166M.
  • Perceptive Advisors added most to Neurocrine Biosciences in Q2 2025, an estimated $17.8M increase.
  • Perceptive Advisors's biggest Q2 2025 reduction was Amicus Therapeutics, cutting an estimated $90.7M.
  • Perceptive Advisors fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $104M.
  • Perceptive Advisors's ten largest holdings make up 54% of its $2.7B portfolio in Q2 2025.
  • Perceptive Advisors opened 20 new positions and closed 22 in Q2 2025.
  • Perceptive Advisors's portfolio value fell 4.7% quarter-over-quarter to $2.7B.

Based on Perceptive Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.